These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1336 related articles for article (PubMed ID: 29957821)

  • 1. Immunosuppressive treatment for proliferative lupus nephritis.
    Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment for lupus nephritis.
    Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive agents for treating IgA nephropathy.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
    Larkins NG; Liu ID; Willis NS; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD002290. PubMed ID: 32297308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Liu ID; Willis NS; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
    von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for minimal change disease in adults with nephrotic syndrome.
    Azukaitis K; Palmer SC; Strippoli GF; Hodson EM
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD001537. PubMed ID: 35230699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for renal vasculitis in adults.
    Walters GD; Willis NS; Cooper TE; Craig JC
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD003232. PubMed ID: 31927782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
    Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
    Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for focal segmental glomerulosclerosis in adults.
    Hodson EM; Sinha A; Cooper TE
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD003233. PubMed ID: 35224732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Hodson EM; Wong SC; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for preventing and treating kidney disease in IgA vasculitis.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD005128. PubMed ID: 36853224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials.
    Palmer SC; Tunnicliffe DJ; Singh-Grewal D; Mavridis D; Tonelli M; Johnson DW; Craig JC; Tong A; Strippoli GFM
    Am J Kidney Dis; 2017 Sep; 70(3):324-336. PubMed ID: 28233655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
    Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-immunosuppressive treatment for IgA nephropathy.
    Tunnicliffe DJ; Reid S; Craig JC; Samuels JA; Molony DA; Strippoli GF
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD003962. PubMed ID: 38299639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for BK virus infection in kidney transplant recipients.
    Wajih Z; Karpe KM; Walters GD
    Cochrane Database Syst Rev; 2024 Oct; 10(10):CD013344. PubMed ID: 39382091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.
    Edwards Mayhew RG; Li T; McCann P; Leslie L; Strong Caldwell A; Palestine AG
    Cochrane Database Syst Rev; 2022 Oct; 10(10):CD014831. PubMed ID: 36315029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
    Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for lupus nephritis.
    Flanc RS; Roberts MA; Strippoli GF; Chadban SJ; Kerr PG; Atkins RC
    Cochrane Database Syst Rev; 2004; (1):CD002922. PubMed ID: 14973998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low protein diets for non-diabetic adults with chronic kidney disease.
    Hahn D; Hodson EM; Fouque D
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.